Channing Global Advisors LLC Sells 600 Shares of Danaher Corporation $DHR

Channing Global Advisors LLC cut its holdings in shares of Danaher Corporation (NYSE:DHR) by 10.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,057 shares of the conglomerate’s stock after selling 600 shares during the quarter. Danaher makes up 0.6% of Channing Global Advisors LLC’s portfolio, making the stock its 27th largest position. Channing Global Advisors LLC’s holdings in Danaher were worth $999,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Red Tortoise LLC grew its holdings in Danaher by 175.0% in the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after buying an additional 98 shares in the last quarter. Ramirez Asset Management Inc. acquired a new position in shares of Danaher in the 2nd quarter valued at approximately $40,000. Costello Asset Management INC bought a new position in shares of Danaher in the first quarter worth about $41,000. Strengthening Families & Communities LLC grew its stake in shares of Danaher by 81.4% during the first quarter. Strengthening Families & Communities LLC now owns 254 shares of the conglomerate’s stock worth $52,000 after buying an additional 114 shares during the last quarter. Finally, Saudi Central Bank bought a new stake in shares of Danaher during the first quarter worth about $52,000. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

DHR opened at $226.24 on Friday. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. The business’s fifty day simple moving average is $212.20 and its 200-day simple moving average is $203.21. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $258.23. The company has a market capitalization of $159.81 billion, a price-to-earnings ratio of 46.65, a PEG ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last posted its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter in the previous year, the firm earned $1.71 earnings per share. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. On average, equities research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio is presently 26.39%.

Analyst Ratings Changes

Several brokerages recently issued reports on DHR. Evercore ISI upped their target price on shares of Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Redburn Partners set a $220.00 price objective on Danaher in a research report on Wednesday, October 8th. Bank of America decreased their price target on shares of Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research note on Monday, September 22nd. TD Cowen increased their target price on Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. Eighteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $243.39.

Insider Buying and Selling

In other news, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the transaction, the senior vice president owned 2,625 shares in the company, valued at $552,352.50. This trade represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Teri List sold 3,298 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the sale, the director owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. The trade was a 13.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 30,248 shares of company stock valued at $6,609,663 over the last ninety days. Company insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.